Vandetanib

Summary

Vandetanib (CHEMBL24828) is an approved small-molecule tyrosine kinase inhibitor (ATC L01EX04) targeting EGFR, KDR, and RET; indicated across 53 conditions including thyroid gland carcinoma and thyroid tumor; with CIViC clinical evidence for 8 variant-indication associations (e.g. RET Fusion in lung non-small cell carcinoma).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EX04
• Targets: 3 (EGFR, KDR, RET)
• Indications: 53 conditions
• Clinical trials: 102
• Precision-oncology evidence (CIViC): 8 variant–indication associations
• Chemistry: 475.4 Da · C22H24BrFN4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL24828
Name	Vandetanib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3081361
ChEBI	CHEBI:49960
ATC	L01EX04
Molecular formula	C22H24BrFN4O2
Molecular weight	475.4
InChIKey	UHTHHESEBZOYNR-UHFFFAOYSA-N

SMILES: CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC

IUPAC name: N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine

ChEBI definition: A quinazoline that is 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline bearing additional methoxy and 4-bromo-2-fluorophenylamino substituents at positions 6 and 4 respectively. Used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Pharmacological roles (ChEBI): tyrosine kinase inhibitor, antineoplastic agent.

Also known as: Caprelsa, GNF-PF-2188, NSC-744325, NSC-760766, Vandetanib, Zactima, ZD-64, ZD-6474, ZD6474, GNF-Pf-2188, vandetanib, SID50112766

Parent form; salt/anhydrous children: CHEMBL533849

Patent coverage: 12,325 distinct patent families (42,230 SureChEMBL compound mentions), from 5 matched compound structure(s). One matched structure accounts for 35,115 (83%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
EGFR	epidermal growth factor receptor	Inhibition	6.52	17.5%	P00533
KDR	kinase insert domain receptor	Inhibition	8	1.1%	P35968
RET	ret proto-oncogene	Inhibition	7	0.4%	P07949

Broader ChEMBL bioactivity targets: 137 (assay-derived). Sample: Leucine-rich repeat serine/threonine-protein kinase 2, Nuclear receptor ROR-gamma, Hormonally up-regulated neu tumor-associated kinase, Receptor tyrosine-protein kinase erbB-2, 5-hydroxytryptamine receptor 2B, Tyrosine-protein kinase Fyn, Macrophage colony-stimulating factor 1 receptor, Tyrosine-protein kinase ABL1, Alpha-2A adrenergic receptor, Vascular endothelial growth factor receptor 1.

Bioactivity

ChEMBL activities: 499 potent at pChembl ≥ 5 of 512 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FLT4	9.96	IC50	0.11	nM	CHEMBL_ACT_24867122
RET	9.89	IC50	0.13	nM	CHEMBL_ACT_24867102
SRC	9.1	IC50	0.79	nM	CHEMBL_ACT_24789092
KDR	8.4	IC50	4	nM	CHEMBL_ACT_24867256
RET	8.4	IC50	4	nM	CHEMBL_ACT_27908483
KDR	8.38	AC50	4.2	nM	CHEMBL_ACT_25167978
RIPK2	8.34	Kd	4.6	nM	CHEMBL_ACT_2907550
RIPK2	8.34	Kd	4.6	nM	CHEMBL_ACT_7578574
EGFR	8.32	Kd	4.8	nM	CHEMBL_ACT_2898732
EGFR	8.32	Kd	4.8	nM	CHEMBL_ACT_7580571
EGFR	8.23	Kd	5.9	nM	CHEMBL_ACT_2898808
EGFR	8.23	Kd	5.9	nM	CHEMBL_ACT_7580573
KDR	8.2	Ki	6.31	nM	CHEMBL_ACT_9630093
RET	8.15	IC50	7	nM	CHEMBL_ACT_24867251
EGFR	8.1	Kd	7.9	nM	CHEMBL_ACT_2898884
EGFR	8.1	Kd	7.9	nM	CHEMBL_ACT_7580575
EGFR	8.06	Kd	8.7	nM	CHEMBL_ACT_2904706
EGFR	8.06	Kd	8.7	nM	CHEMBL_ACT_7580577
KDR	8.05	IC50	9	nM	CHEMBL_ACT_1516652
RET	8.05	IC50	9	nM	CHEMBL_ACT_22952710
EGFR	8.05	Kd	8.9	nM	CHEMBL_ACT_2898922
ABL1	8.05	Kd	9	nM	CHEMBL_ACT_7580564
EGFR	8.05	Kd	8.9	nM	CHEMBL_ACT_7580576
EGFR	8.02	Kd	9.5	nM	CHEMBL_ACT_19218710
EGFR	8.02	Kd	9.5	nM	CHEMBL_ACT_2898694
EGFR	8.02	Kd	9.6	nM	CHEMBL_ACT_2898770
EGFR	8.02	Kd	9.5	nM	CHEMBL_ACT_7580570
EGFR	8.02	Kd	9.6	nM	CHEMBL_ACT_7580572
EGFR	8.01	AC50	9.8	nM	CHEMBL_ACT_25168844
ABL1	8.01	Kd	9.8	nM	CHEMBL_ACT_7580557

Target pathways

Aggregated over 3 target gene(s): EGFR, KDR, RET.

Top Reactome pathways

48 total, by targets touching each:

Pathway	Targets	Genes
RAF/MAP kinase cascade	2	EGFR, RET
Signaling by ERBB2	1	EGFR
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	1	EGFR
Signaling by ERBB4	1	EGFR
SHC1 events in ERBB2 signaling	1	EGFR
PLCG1 events in ERBB2 signaling	1	EGFR
PIP3 activates AKT signaling	1	EGFR
Signaling by EGFR	1	EGFR
GRB2 events in EGFR signaling	1	EGFR
GAB1 signalosome	1	EGFR
SHC1 events in EGFR signaling	1	EGFR
EGFR downregulation	1	EGFR
Neuropilin interactions with VEGF and VEGFR	1	KDR
VEGF binds to VEGFR leading to receptor dimerization	1	KDR
GRB2 events in ERBB2 signaling	1	EGFR
PI3K events in ERBB2 signaling	1	EGFR
EGFR interacts with phospholipase C-gamma	1	EGFR
Integrin cell surface interactions	1	KDR
EGFR Transactivation by Gastrin	1	EGFR
Constitutive Signaling by Aberrant PI3K in Cancer	1	EGFR
VEGFA-VEGFR2 Pathway	1	KDR
Signal transduction by L1	1	EGFR
VEGFR2 mediated cell proliferation	1	KDR
Constitutive Signaling by EGFRvIII	1	EGFR
Inhibition of Signaling by Overexpressed EGFR	1	EGFR
ERBB2 Regulates Cell Motility	1	EGFR
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	EGFR
ERBB2 Activates PTK6 Signaling	1	EGFR
RET signaling	1	RET
Cargo recognition for clathrin-mediated endocytosis	1	EGFR

Dominant GO biological processes

GO term	Targets
positive regulation of cell migration	3
positive regulation of MAPK cascade	3
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	3
protein phosphorylation	3
cell surface receptor protein tyrosine kinase signaling pathway	3
positive regulation of protein phosphorylation	2
signal transduction	2
positive regulation of cell population proliferation	2
neuron differentiation	2
negative regulation of apoptotic process	2
epithelial cell proliferation	2
positive regulation of epithelial cell proliferation	2
positive regulation of ERK1 and ERK2 cascade	2
MAPK cascade	2
cell morphogenesis	1

Indications & clinical

Indications

53 indications (7 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thyroid gland carcinoma	4	MONDO:0015075	EFO:0002892
thyroid tumor	4	MONDO:0015074	EFO:0003841
neoplasm	4	MONDO:0005070	EFO:0000616
thyroid gland papillary carcinoma	4	MONDO:0005075	EFO:0000641
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
lung neoplasm	3	MONDO:0021117	MONDO:0008903
mesothelioma	2	MONDO:0005065	EFO:0000588
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
prostate carcinoma	2	MONDO:0005159	EFO:0001663
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
clear cell renal carcinoma	2	MONDO:0005005	EFO:0000349
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
colorectal adenocarcinoma	2	MONDO:0005008	EFO:0000365
glioblastoma	2	MONDO:0018177	EFO:0000519
oligoastrocytoma	2	MONDO:0016702	EFO:0000630
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
anaplastic astrocytoma	2	MONDO:0016684	EFO:0002499
anaplastic oligodendroglioma	2	MONDO:0016696	EFO:0002501
breast neoplasm	2	MONDO:0021100	EFO:0003869
head and neck cancer	2	MONDO:0005627	EFO:0006859
gliosarcoma	2	MONDO:0016681	EFO:1001465
thyroid gland follicular carcinoma	2	MONDO:0005034	EFO:0000501
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
kidney cancer	2	MONDO:0002367	MONDO:0002367
ovarian cancer	2	MONDO:0008170	MONDO:0008170
ureter cancer	2	MONDO:0008627	MONDO:0008627
gastrointestinal stromal tumor	2	MONDO:0011719	MONDO:0011719
colorectal neoplasm	2	MONDO:0005335	EFO:0004142
neuroblastoma	1	MONDO:0005072	EFO:0000621
carcinoma of esophagus	1	MONDO:0019086	EFO:0002916
diffuse intrinsic pontine glioma	1	MONDO:0006033	EFO:1000026
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158
rectal cancer	1	MONDO:0006519	EFO:1000657
glioma	1	MONDO:0021042	MONDO:0100342
adrenal gland pheochromocytoma	1	MONDO:0004974	EFO:0000239
carcinoma	1	MONDO:0004993	EFO:0000313
paraganglioma	1	MONDO:0000448	EFO:1000453
adenocarcinoma	1	MONDO:0004970	MONDO:0003219

11 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 102.

Phase distribution

Phase	Trials
PHASE2	49
PHASE1	33
PHASE3	9
PHASE1/PHASE2	6
Not specified	4
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01496313	PHASE4	COMPLETED	To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
NCT04211337	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT00312377	PHASE3	COMPLETED	ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
NCT00364351	PHASE3	COMPLETED	Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
NCT00404924	PHASE3	COMPLETED	ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
NCT00410761	PHASE3	COMPLETED	An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
NCT00418886	PHASE3	COMPLETED	Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
NCT01298323	PHASE3	COMPLETED	Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
NCT01876784	PHASE3	COMPLETED	Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
NCT04760288	PHASE3	WITHDRAWN	A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
NCT02299999	PHASE2	ACTIVE_NOT_RECRUITING	SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
NCT06482086	PHASE2	RECRUITING	Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
NCT00034918	PHASE2	COMPLETED	This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer
NCT00047788	PHASE2	COMPLETED	Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer
NCT00047840	PHASE2	COMPLETED	This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
NCT00059722	PHASE2	COMPLETED	This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
NCT00066313	PHASE2	COMPLETED	ZD6474 in Treating Patients With Small Cell Lung Cancer
NCT00071188	PHASE2	COMPLETED	ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00098345	PHASE2	COMPLETED	Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
NCT00290537	PHASE2	TERMINATED	Phase II Study of ZD6474 in Advanced NSCLC
NCT00358956	PHASE2	COMPLETED	A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
NCT00402896	PHASE2	TERMINATED	Malignant Pleural Effusion With ZD6474
NCT00410189	PHASE2	COMPLETED	BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
NCT00441142	PHASE1/PHASE2	COMPLETED	Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
NCT00445549	PHASE2	TERMINATED	Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00454116	PHASE2	COMPLETED	A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
NCT00459043	PHASE2	COMPLETED	Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck
NCT00459121	PHASE2	TERMINATED	Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
NCT00481845	PHASE2	TERMINATED	Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
NCT00494481	PHASE2	COMPLETED	E3 Breast Cancer Taxotere Combination
NCT00498797	PHASE2	COMPLETED	E3-Hormone Refractory Prostrate Cancer Taxotere Combination
NCT00500292	PHASE2	COMPLETED	A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
NCT00508001	PHASE2	COMPLETED	Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
NCT00514046	PHASE1/PHASE2	COMPLETED	Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
NCT00537095	PHASE2	COMPLETED	Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
NCT00597116	PHASE2	TERMINATED	An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
NCT00613626	PHASE2	COMPLETED	Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT00659438	PHASE2	COMPLETED	Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
NCT00683787	PHASE2	TERMINATED	Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
NCT00686036	PHASE2	TERMINATED	Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy

Clinical evidence (CIViC)

Variant × indication × effect (8 predictive associations from 9 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
RET Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Vandetanib	CIViC B	EID4848 +1
SDHB Mutation	Hereditary Renal Cell Carcinoma	Sensitivity/Response	Vandetanib + Metformin	CIViC B	EID7959
AKT2 Amplification	Lung Adenocarcinoma	Sensitivity/Response	Vandetanib + Everolimus	CIViC C	EID1621
KIF5B::RET Fusion	Lung Adenocarcinoma	Sensitivity/Response	Everolimus + Vandetanib	CIViC C	EID1622
KIF5B::RET Fusion	Lung Adenocarcinoma	Sensitivity/Response	Vandetanib	CIViC C	EID698
RET Overexpression	Estrogen-receptor Negative Breast Cancer	Sensitivity/Response	Vandetanib	CIViC D	EID2992
RET Overexpression	Breast Cancer	Sensitivity/Response	Vandetanib	CIViC D	EID740
KIF5B::RET Fusion AND RET G810A	Lung Non-small Cell Carcinoma	Resistance	Vandetanib	CIViC D	EID4852

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

282 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, KDR, RET
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, KDR, RET
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, KDR, RET
Pazopanib	ChEMBL + PubChem	Phase 4 (approved)	EGFR, KDR, RET
SELUMETINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, KDR, RET
ALECTINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
AXITINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
BRIGATINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
CABOZANTINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
CERITINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
DASATINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
ERLOTINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
FEDRATINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
IBRUTINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
PONATINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
SORAFENIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
SUNITINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
VEMURAFENIB	ChEMBL	Phase 4 (approved)	EGFR, KDR, RET
ALISERTIB	ChEMBL	Phase 3	EGFR, KDR, RET
BARASERTIB	ChEMBL	Phase 3	EGFR, KDR, RET
BRIVANIB	ChEMBL	Phase 3	EGFR, KDR, RET
CANERTINIB	ChEMBL	Phase 3	EGFR, KDR, RET
CEDIRANIB	ChEMBL	Phase 3	EGFR, KDR, RET
DOVITINIB	ChEMBL	Phase 3	EGFR, KDR, RET
LESTAURTINIB	ChEMBL	Phase 3	EGFR, KDR, RET
LINIFANIB	ChEMBL	Phase 3	EGFR, KDR, RET
MOTESANIB	ChEMBL	Phase 3	EGFR, KDR, RET
QUERCETIN	ChEMBL	Phase 3	EGFR, KDR, RET
SARACATINIB	ChEMBL	Phase 3	EGFR, KDR, RET
VATALANIB	ChEMBL	Phase 3	EGFR, KDR, RET
AEE-788	ChEMBL	Phase 2	EGFR, KDR, RET
BEMCENTINIB	ChEMBL	Phase 2	EGFR, KDR, RET
CENISERTIB	ChEMBL	Phase 2	EGFR, KDR, RET
CEP-32496	ChEMBL	Phase 2	EGFR, KDR, RET
DEFOSBARASERTIB	ChEMBL	Phase 2	EGFR, KDR, RET
DORAMAPIMOD	ChEMBL	Phase 2	EGFR, KDR, RET
FORETINIB	ChEMBL	Phase 2	EGFR, KDR, RET
ILORASERTIB	ChEMBL	Phase 2	EGFR, KDR, RET
OSI-632	ChEMBL	Phase 2	EGFR, KDR, RET
R-406	ChEMBL	Phase 2	EGFR, KDR, RET
SU-014813	ChEMBL	Phase 2	EGFR, KDR, RET
TOZASERTIB	ChEMBL	Phase 2	EGFR, KDR, RET
Binimetinib	PubChem	Approved	EGFR, KDR, RET
DACOMITINIB	ChEMBL + PubChem	Phase 4 (approved)	EGFR, RET
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	EGFR, KDR
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	KDR, RET
SELPERCATINIB	ChEMBL + PubChem	Phase 4 (approved)	KDR, RET
ABEMACICLIB	ChEMBL	Phase 4 (approved)	EGFR, KDR
ACALABRUTINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR
BOSUTINIB	ChEMBL	Phase 4 (approved)	EGFR, RET
ENTRECTINIB	ChEMBL	Phase 4 (approved)	KDR, RET
GILTERITINIB	ChEMBL	Phase 4 (approved)	EGFR, RET
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	EGFR, KDR
IMATINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR
INFIGRATINIB	ChEMBL	Phase 4 (approved)	KDR, RET
LAPATINIB	ChEMBL	Phase 4 (approved)	EGFR, RET
LENVATINIB	ChEMBL	Phase 4 (approved)	KDR, RET
NERATINIB	ChEMBL	Phase 4 (approved)	EGFR, KDR
NICLOSAMIDE	ChEMBL	Phase 4 (approved)	EGFR, KDR